top of page
IMG_5089_edited.jpg

Thomas Malcolm PhD - COO & CSO
KERMODE BIOTECHNOLOGIES

Dr. Thomas Malcolm brings nearly 25 years of expertise in biochemistry and molecular biology of viruses, coupled with extensive business acumen, to the executive team of Kermode Biotechnologies Inc., a company he co-founded to develop innovative solutions for vaccine and therapeutic challenges related to complex animal and livestock viral infections.

Dr. Malcolm also serves as the President, Chief Scientific and Innovations Officer, and Board Member for Caravan Biologix Inc., a company he founded that focuses on creating novel therapeutics for treating solid tumor cancers and other human diseases.

Throughout his career, Dr. Malcolm has successfully raised nearly $20 million USD for biotechnology companies, guiding them from the early and conceptual stages to critical funding rounds. His strategic vision and fundraising prowess have been instrumental in positioning these companies for success and growth. Dr. Malcolm has been pivotal in advancing several groundbreaking technologies, including CRISPR gene editing of viruses, novel drug delivery systems, and toxoid vaccines.

In addition to his executive roles, Dr. Malcolm is a member of the Scientific Advisory Board for Cila Therapeutics Inc., located in Boston, MA, a company developing inhaled therapies for treating Primary Ciliary Dyskinesia (PCD) and late-stage SARS-CoV-2 hydrofluidic lung infections. He also serves as a scientific advisor and former CSO for BioMark Diagnostics Inc., based in Vancouver, Canada, a company developing metabolomic diagnostics. Dr. Malcolm is a Director on the US Board of Directors for Emergex Vaccines Inc. located in the United Kingdom and serves as a science advisor for the Hippocrates Opportunities Fund, headquartered in New York, NY.

Dr. Malcolm founded Criterion BioScience Research Group in 2012, a life sciences advisory group focusing on emergent biotechnologies. He has also served as a Senior Biochemist at Siemens Healthcare Diagnostics and has held multiple executive roles as CEO, COO, and CSO throughout his career.

Dr. Malcolm's research on viruses and cancers has been published in numerous high-impact journals, and he holds several patents. He earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada, and continued his studies as a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Mount Sinai School of Medicine in New York, NY.

bottom of page